{"name":"Supernus Pharmaceuticals, Inc.","slug":"supernus-pharmaceuticals-inc","ticker":"","exchange":"","domain":"supernus.com","description":"","hq":"Rockville","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2019-01-01","label":"ZULRESSO® first approved","drug":"ZULRESSO®","drugSlug":"zulresso","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"SPN-810 (36 mg)","genericName":"SPN-810 (36 mg)","slug":"spn-810-36-mg","indication":"Disruptive mood dysregulation disorder (DMDD)","status":"phase_3"},{"name":"BIS-001 ER","genericName":"BIS-001 ER","slug":"bis-001-er","indication":"Other","status":"phase_1"},{"name":"SAGE-904","genericName":"SAGE-904","slug":"sage-904","indication":"Other","status":"phase_1"},{"name":"SPN-812","genericName":"SPN-812","slug":"spn-812","indication":"Other","status":"marketed"},{"name":"TPM XR","genericName":"TPM XR","slug":"tpm-xr","indication":"Other","status":"phase_1"},{"name":"MYOBLOC","genericName":"MYOBLOC","slug":"myobloc","indication":"Cervical dystonia (torticollis)","status":"marketed"},{"name":"Phase 2; High Dose MYOBLOC","genericName":"Phase 2; High Dose MYOBLOC","slug":"phase-2-high-dose-myobloc","indication":"Other","status":"phase_2"},{"name":"Phase 2; Low Dose MYOBLOC","genericName":"Phase 2; Low Dose MYOBLOC","slug":"phase-2-low-dose-myobloc","indication":"Other","status":"phase_2"},{"name":"SPN-538","genericName":"SPN-538","slug":"spn-538","indication":"Other","status":"marketed"},{"name":"SPN-804O","genericName":"SPN-804O","slug":"spn-804o","indication":"Other","status":"phase_1"},{"name":"SPN-810M","genericName":"SPN-810M","slug":"spn-810m","indication":"Other","status":"phase_1"},{"name":"SPN-817","genericName":"SPN-817","slug":"spn-817","indication":"Other","status":"phase_2"},{"name":"SPN-817, Treatment B","genericName":"SPN-817, Treatment B","slug":"spn-817-treatment-b","indication":"Other","status":"phase_1"},{"name":"SPN-817, Treatment C","genericName":"SPN-817, Treatment C","slug":"spn-817-treatment-c","indication":"Other","status":"phase_1"},{"name":"Topiramate ER","genericName":"Topiramate ER","slug":"topiramate-er","indication":"Other","status":"phase_1"},{"name":"Topiramate IR","genericName":"Topiramate IR","slug":"topiramate-ir","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"SPN-810 (18 mg)","genericName":"SPN-810 (18 mg)","slug":"spn-810-18-mg","indication":"Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults","status":"phase_3"},{"name":"Oxcarbazepine XR","genericName":"Oxcarbazepine XR","slug":"oxcarbazepine-xr","indication":"Partial-onset seizures (monotherapy and adjunctive therapy)","status":"phase_3"},{"name":"SAGE-547","genericName":"SAGE-547","slug":"sage-547","indication":"Status epilepticus","status":"phase_3"},{"name":"SPN-812 (600mg, QD)","genericName":"SPN-812 (600mg, QD)","slug":"spn-812-600mg-qd","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"marketed"},{"name":"ZULRESSO®","genericName":"ZULRESSO®","slug":"zulresso","indication":"Postpartum depression","status":"marketed"}]}],"pipeline":[{"name":"SPN-810 (36 mg)","genericName":"SPN-810 (36 mg)","slug":"spn-810-36-mg","phase":"phase_3","mechanism":"SPN-810 is a proprietary formulation of a divalproex sodium extended-release product designed to treat disruptive mood dysregulation disorder (DMDD).","indications":["Disruptive mood dysregulation disorder (DMDD)"],"catalyst":""},{"name":"SPN-810 (18 mg)","genericName":"SPN-810 (18 mg)","slug":"spn-810-18-mg","phase":"phase_3","mechanism":"SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control.","indications":["Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults"],"catalyst":""},{"name":"BIS-001 ER","genericName":"BIS-001 ER","slug":"bis-001-er","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SAGE-904","genericName":"SAGE-904","slug":"sage-904","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-812","genericName":"SPN-812","slug":"spn-812","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TPM XR","genericName":"TPM XR","slug":"tpm-xr","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MYOBLOC","genericName":"MYOBLOC","slug":"myobloc","phase":"marketed","mechanism":"MYOBLOC is a botulinum toxin type B that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.","indications":["Cervical dystonia (torticollis)","Blepharospasm","Strabismus"],"catalyst":""},{"name":"Oxcarbazepine XR","genericName":"Oxcarbazepine XR","slug":"oxcarbazepine-xr","phase":"phase_3","mechanism":"Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures.","indications":["Partial-onset seizures (monotherapy and adjunctive therapy)","Generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""},{"name":"Phase 2; High Dose MYOBLOC","genericName":"Phase 2; High Dose MYOBLOC","slug":"phase-2-high-dose-myobloc","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phase 2; Low Dose MYOBLOC","genericName":"Phase 2; Low Dose MYOBLOC","slug":"phase-2-low-dose-myobloc","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SAGE-547","genericName":"SAGE-547","slug":"sage-547","phase":"phase_3","mechanism":"SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit.","indications":["Status epilepticus"],"catalyst":""},{"name":"SPN-538","genericName":"SPN-538","slug":"spn-538","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-804O","genericName":"SPN-804O","slug":"spn-804o","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-810M","genericName":"SPN-810M","slug":"spn-810m","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-812 (600mg, QD)","genericName":"SPN-812 (600mg, QD)","slug":"spn-812-600mg-qd","phase":"marketed","mechanism":"SPN-812 is a selective norepinephrine reuptake inhibitor that increases norepinephrine availability in the central nervous system to improve attention and executive function.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"],"catalyst":""},{"name":"SPN-817","genericName":"SPN-817","slug":"spn-817","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-817, Treatment B","genericName":"SPN-817, Treatment B","slug":"spn-817-treatment-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-817, Treatment C","genericName":"SPN-817, Treatment C","slug":"spn-817-treatment-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topiramate ER","genericName":"Topiramate ER","slug":"topiramate-er","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topiramate IR","genericName":"Topiramate IR","slug":"topiramate-ir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZULRESSO®","genericName":"ZULRESSO®","slug":"zulresso","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-2/gamma-2","indications":["Postpartum depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVWh1LXZQejkySmpfbmdEcEVkQm9YQUxRTjhXUXlBVEU4dWl0VUh0cVNCc0VoX25LYUNXVXlPdDl0TUNsX0dISzh0bjJEQlR4bDRaTE8tN0VkdGNGQWZURWUtdllpZUc5a25vUVFTN1djTkdDWEhyYThPanJpOFItVHFxck80WEFHT2pYY19pMmNTTUJSSUpFRXVaeXRhYTBNcGF5VGZ1MzRqUWlVSTlCM29hV0lvSG8xTHVQWVVacWo?oc=5","date":"2026-03-27","type":"pipeline","source":"The Motley Fool","summary":"Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year - The Motley Fool","headline":"Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOZmpobWU3TlM3MTdmaW5HcnZhc3JIUWdIT244eHRBcHZKMHc1VDN3Nms4VmZ3MFlQbS1PbnNTUlVxNHVzbDM3elk3RlczZlQ5WnVOemN4T2NWazFjNllualVDR0ZjY2U0ZE9JM2xJeHdqRW5FTGpBNFl5WW5FUzZSZkY5SE9iZzBEdU9zcGgzejJxcnJqSHpVVF9sRzFwSXJ0LUpYZDRKQXFsV0Z3SGE0aUxsRkdsZG91UUY5VHlyYzlfdG8?oc=5","date":"2026-03-11","type":"pipeline","source":"National Today","summary":"Jefferies Financial Group Boosts Stake in Supernus Pharmaceuticals - National Today","headline":"Jefferies Financial Group Boosts Stake in Supernus Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQdW5DWTZtWHd4czU2MWJyMFdybl85WDU2d2x4a1NoYVF0emI5X2F4VmNRVWtxbjZ1UWtuRjRiZ1VSMGRhUlVVclJQVkt4QVMwNEdKWm91X0RZV2FsdEJZMUtnN0NiamZEdGM4ZDNPTGFMd3hvbURXRlhvRU9OYUY4Qk1jUUpFVTF2aFBxbXVpeTkzUV9QNmtFeFFueDJQbXRoVGVad3VWLUhhbjA1VkhVMHZRZWFDTE1yYjQxYTlkdTFEQWplVlE?oc=5","date":"2026-03-10","type":"pipeline","source":"National Today","summary":"Victory Capital Management Reduces Stake in Supernus Pharmaceuticals - National Today","headline":"Victory Capital Management Reduces Stake in Supernus Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPS0tOcVVVYU9DTk9ISFZLREg5eHRheXpVMzBBaHBDWUkzQ0dmQnRYQnZDUjN3YzVRRVNZSThITUQzbThIRWJ5d3VLWHV2bUlES0J4V1hGRG1YMVV1LVhUQ2dkZzVFdjVhV2dxMDh4SHp0bkxNUHVIbWZjWWlYQ19zaDhOcDhGUHNnV2c?oc=5","date":"2026-02-25","type":"earnings","source":"Yahoo Finance","summary":"Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance","headline":"Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOQlJ5MjNpWk81aWE4Njdld3RrNGg4MzBITHFxV3FMeG84WmxfbVBXTHVSMktUQXJtbENLMWIxQ3NxTzVQeEZqaFdXTExNWTV6R1JxS1dCQzZrelRQZDRFUHlJb2ZqSHZ0bmtxTnlXSXM3eTE1ZHdIU25OTWRyZ1pEVjhwYlBxY2UzWmpxSU5nMzRuRXBjTTNxZnpXM1ZnQkZS?oc=5","date":"2025-08-01","type":"trial","source":"The Clinical Trial Vanguard","summary":"Supernus Pharma Completes Sage Therapeutics Acquisition - The Clinical Trial Vanguard","headline":"Supernus Pharma Completes Sage Therapeutics Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNbnR1S0tKYjdDMmRiQ2pZdEdvR2ZvQUFLTkd1N0E1Wm1rSjJXTDNhMTNubUtzS0xSS2c5Z1FuMGpuOWJ3WTZKOWVSQWxjTEhESGM0TDZoMTdUWVIxaF9TUFJtUEl2bHhZMVk5UlNPR1lrRTdDbjhua1M0NmJFdndXTFhWMzVyUFNrZEpkSmI5R0dLTmZuZXBmRkdWOUdxOFlia2FSUFJkMFhOTU5zWmxfa2Ixa2RGZTVnQ2k2ejlGbDJobXluazBGRktUT1NudjVUQllPUkljeXMxQmc?oc=5","date":"2025-07-31","type":"pipeline","source":"globenewswire.com","summary":"Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - globenewswire.com","headline":"Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOZTJhVm9QU1VoYlByaFdiSUFLZmtRYXVQR2RUMG5FOTlwV19tblpvbkdnZEhiOHl5UG8xV1I2bXlFdy1hMGx5YWxYdkFWdUh3ZFlHWnhjaVlzeTk3ZnEtYzlmZ2JYQUFNN0Z6WnVwZUVhV3ZBOFlpSkhVVzk2dmZUcXhZc05mbzNQejV5ZWhLMERmOTBuazgta2xB?oc=5","date":"2025-06-30","type":"pipeline","source":"Fierce Pharma","summary":"Sage lays off entire staff of 338 amid takeover by Supernus - Fierce Pharma","headline":"Sage lays off entire staff of 338 amid takeover by Supernus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTldZY3NXVDYwMUNSZjhnTGpvcGQ1NkRHaVFmU1RNN1JJeEJTVGRsc2ZSYkgyQ01BYkpJbFlaTUluTS1WYmNrbVROdG9Ha3pmczBiaUsxY2E0SkxzdUpDVTlNLVZNLUpGR05LOEljVS0xWFlBR3dNUnVyNjVlWW9OSVZkc2dGdlpIRlpLVDQ1TmhGM0kxLWd6RlRqUkVDWjRSNklZSWdabVo?oc=5","date":"2025-06-16","type":"deal","source":"Pharmaceutical Technology","summary":"Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology","headline":"Supernus makes depression drug play with $795m Sage buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQOVNqSlVFeFVxc0VQaVFoaG4ycXZpdVdNVmx4SVprZzZkZlNTd3VfYlFnQXZVUzREdTlWWUEySXlOT05aWHBPRklOVG4ycGZDS3JIYzJZU2RHc0NfaUdPM0E1Xzh3QkFENzhEeTBzNmZOeEc1QXd5WWIyS0JaQ0JZR2tVOE45ZGVYWVVmYkxFZTlCRFNzN2c0?oc=5","date":"2025-06-16","type":"pipeline","source":"BioPharma Dive","summary":"Sage, following setbacks, to sell to Supernus for $561M - BioPharma Dive","headline":"Sage, following setbacks, to sell to Supernus for $561M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPeFFhZGEzYTNjXzhFQjZsODVUOFJwQVpOaUs0OVpfemt4OW9DUWY0cVBOc1JHd05tNTZwUVlEQlJsV1Jicnhvd1duQUtCdDRmaElzZWF5X0RRYmdZY0ZfeFcwSkxFNGlmanJsUk1JdnA1ampiQzRkU3Zvd0NWVkVmX1dwUnlkb3FHSUxaVGxfVUYxRkdHa05TN05xdXBFb2I0T3M2N2VfTVhaeEU?oc=5","date":"2025-06-16","type":"deal","source":"Seeking Alpha","summary":"Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha","headline":"Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNeWxzZXRrcVFKTXJ3M0ptUWNrbWhyRDhXS081TTNFUnpPQmc4YktkRS03R1NsR3EtYVJIWHlpMGdWYlo2Z21sQ2JBWUNFWTVUdkZ1RE9yXy0xSExuZTFvUFZXSTRCYUhYTUJaUUJJZGJIRFdWajVpV0Q5QVo1SDdxMDNzUV9Md0x5aUNvZGhhaU5rRWpVMl82RC0zcWJ1QmRUbnZ2UXNhY1FXeDFuYXVHbThoMWNETEYtMXhwVmhUeWdyLXJsSFgyM2d1RnpuTXFyaFZuRWVoZjlhVmNVb3JtLU85RHZxMGJQMlh4RFplR3NTOTFMeGI0X2NkNDNHNTRBSktmMnpTb1M4ZlZHZ2c?oc=5","date":"2025-06-16","type":"deal","source":"globenewswire.com","summary":"Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - globenewswire.com","headline":"Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOU2YzNHFJcFE5bUFJWWhBSlIxU1U0MUQtLTZYWURveTVjSnB1bG5uOHVlcEJsMjRFcmNwZWtEdVBnVGp4QndKZG9sLVBNSm5LaHU2OHpUYUVXek1OVFEzbXhQeldyalNwdlJKT0J3X1l2UDFNSUhidFdHRWtOQlU3MkViTWdTNXRWNXYycm5OYjRYYkswNzJfaWNwWGxFbVBXV0V3UmYwakZnQmF3dmxxU3lxTGZ6RXkxSVVzdlVOSHY?oc=5","date":"2025-06-16","type":"deal","source":"Fierce Pharma","summary":"Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae - Fierce Pharma","headline":"Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"phase_3":4,"phase_1":9,"marketed":5,"phase_2":3},"enrichmentLevel":0,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}